###begin article-title 0
Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma
###end article-title 0
###begin p 1
Conceived and designed the experiments: XF. Performed the experiments: DG XF JR DT AP EE. Analyzed the data: DG XF JR DT BW LS AP EE. Contributed reagents/materials/analysis tools: LS. Wrote the paper: DG XF JR DT BW LS AP EE.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
While neurosphere- as well as xenograft tumor-initiating cells have been identified in gliomas, the resemblance between glioma cells and neural stem/progenitor cells as well as the prognostic value of stem/progenitor cell marker expression in glioma are poorly clarified.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 1270 1277 <span type="species:ncbi:9606">patient</span>
Viable glioma cells were characterized for surface marker expression along the glial genesis hierarchy. Six low-grade and 17 high-grade glioma specimens were flow-cytometrically analyzed for markers characteristics of stem cells (CD133); glial progenitors (PDGFRalpha, A2B5, O4, and CD44); and late oligodendrocyte progenitors (O1). In parallel, the expression of glial fibrillary acidic protein (GFAP), synaptophysin and neuron-specific enolase (NSE) was immunohistochemically analyzed in fixed tissue specimens. Irrespective of the grade and morphological diagnosis of gliomas, glioma cells concomitantly expressed PDGFRalpha, A2B5, O4, CD44 and GFAP. In contrast, O1 was weakly expressed in all low-grade and the majority of high-grade glioma specimens analyzed. Co-expression of neuronal markers was observed in all high-grade, but not low-grade, glioma specimens analyzed. The rare CD133 expressing cells in low-grade glioma specimens typically co-expressed vessel endothelial marker CD31. In contrast, distinct CD133 expression profiles in up to 90% of CD45-negative glioma cells were observed in 12 of the 17 high-grade glioma specimens and the majority of these CD133 expressing cells were CD31 negative. The CD133 expression correlates inversely with length of patient survival. Surprisingly, cytogenetic analysis showed that gliomas contained normal and abnormal cell karyotypes with hitherto indistinguishable phenotype.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 448 455 448 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
This study constitutes an important step towards clarification of lineage commitment and differentiation blockage of glioma cells. Our data suggest that glioma cells may resemble expansion of glial lineage progenitor cells with compromised differentiation capacity downstream of A2B5 and O4 expression. The concurrent expression of neuronal markers demonstrates that high-grade glioma cells are endowed with multi-lineage differentiation potential in vivo. Importantly, enhanced CD133 expression marks a poor prognosis in gliomas.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 731 738 731 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 824 831 824 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1026 1029 1022 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Bouvier1">[1]</xref>
###xml 1030 1033 1026 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Shoshan1">[3]</xref>
###xml 1134 1137 1130 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Louis1">[4]</xref>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
Gliomas, the most common primary tumors in the adult central nervous system, are currently classified according to their morphological features, into low- and high-grade glioma. Cells of low-grade (I and II) gliomas are well differentiated with clear histological similarity to astrocyte or oligodendrocyte lineage. High-grade (III and IV) gliomas are more anaplastic, with features resembling immature astrocytes, oligodendrocytes or a mixture of both types. Low-grade gliomas are frequently diagnosed in relatively young patients and many of these eventually develop into anaplastic gliomas which subsequently progress to the so-called secondary glioblastoma (GBM). In contrast, the GBM in older patients are mostly diagnosed as de novo without any clinically detectable history. It is unclear whether the early stages of de novo GBM development resemble low-grade gliomas. Although previous studies suggested glioma expression of oligodendrocyte progenitor cell antigen NG2 and PDGFRalpha, and transcription factor Olig1/2 [1]-[3], the lineage commitment and the stage of differentiation blockage of glioma cells are not clarified [4].
###end p 9
###begin p 10
###xml 91 94 91 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Louis1">[4]</xref>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Beier1">[5]</xref>
###xml 306 309 306 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Sakariassen1">[6]</xref>
###xml 486 487 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 619 622 619 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Singh1">[7]</xref>
###xml 623 626 623 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Galli1">[9]</xref>
###xml 761 764 761 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Galli1">[9]</xref>
###xml 835 836 835 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 945 953 945 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1042 1046 1042 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Reynolds1">[10]</xref>
###xml 1244 1252 1244 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kondo1">[11]</xref>
###xml 1407 1414 1407 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1594 1598 1594 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Hill1">[12]</xref>
###xml 1600 1604 1600 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kelly1">[13]</xref>
###xml 1773 1777 1773 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Fan1">[14]</xref>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 1576 1581 <span type="species:ncbi:10090">mouse</span>
For decades, the median survival of high-grade gliomas has not been significantly improved [4]. In efforts to identify crucial cellular and molecular targets for glioma treatment, recent studies have indicated that all grades of gliomas contain putative tumor stem cells, which can be CD133+ or CD133-[5], [6]. These cells are endowed with self-renewal and multi-lineage differentiation capacity in neurosphere-forming assay, a surrogate assay for neural stem cells. Particularly, CD133+ putative GBM stem cells were capable of xenograft GBM initiation where the CD133- GBM cells from the same patients failed to do so [7]-[9]. Compared with normal neural stem/progenitor cells, glioma derived cells showed an enhanced and more aggressive self-renewal capacity [9]. Thus, neurosphere-forming glioma cells, which may or may not be CD133+, are likely to be the crucial targets for successful treatment. However, neurosphere-forming capacity is an in vitro growth factor dependent feature common to neural stem cells as well as progenitor cells [10]; it is also likely that cells normally not endowed with such capacity can gain neurosphere-forming capacity due to transformation mechanisms. In fact, glial lineage restricted progenitor cells can in vitro be reprogrammed to acquire multi-lineage differentiation capacity in an environmental cue dependent manner [11]. It has been unclear whether glioma cells in vivo are endowed with a multi-lineage differentiation potential. Similarly, xeno-transplantation may only assess those tumor cells capable of adapting to growth in a mouse environment [12], [13]. It is therefore controversial whether neurosphere- or xenograft tumor- initiating glioma cells represent the authentic glioma stem cells, from which gliomas originate [14].
###end p 10
###begin p 11
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Temple1">[15]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Weissman1">[16]</xref>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Uchida1">[17]</xref>
###xml 737 741 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-MayerProschel1">[18]</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Piper1">[19]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Rao1">[20]</xref>
###xml 982 986 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Gregori1">[21]</xref>
###xml 1107 1111 1107 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Rao1">[20]</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Dietrich1">[27]</xref>
###xml 1137 1144 1137 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1240 1248 1240 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1403 1407 1403 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Gregori1">[21]</xref>
###xml 1409 1413 1409 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu1">[28]</xref>
###xml 1626 1630 1618 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Sim1">[22]</xref>
###xml 1632 1636 1624 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Roy1">[25]</xref>
###xml 1638 1642 1630 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Raff1">[26]</xref>
###xml 1860 1864 1848 1852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Gregori1">[21]</xref>
###xml 1866 1870 1854 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Dietrich1">[27]</xref>
###xml 1872 1876 1860 1864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Armstrong1">[29]</xref>
###xml 1908 1916 1896 1904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1993 1997 1981 1985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Raff1">[26]</xref>
###xml 2181 2185 2169 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kondo1">[11]</xref>
###xml 2241 2245 2225 2229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Sim1">[22]</xref>
###xml 2246 2250 2230 2234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Scolding2">[24]</xref>
###xml 2252 2256 2236 2240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Armstrong1">[29]</xref>
###xml 2308 2312 2292 2296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu1">[28]</xref>
###xml 2314 2318 2298 2302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Alfei1">[30]</xref>
###xml 634 639 <span type="species:ncbi:9606">human</span>
###xml 1601 1606 <span type="species:ncbi:9606">human</span>
###xml 2258 2263 <span type="species:ncbi:9606">Human</span>
In analogy with the well characterized hematopoiesis hierarchy, mature neural cells are derived from the neural stem cells via multiple progressively committed/differentiated intermediate progenitor cells [15]. The differentiation stages along the hematopoietic hierarchy of primitive hematopoietic cells and leukemic cells can, to a significant extent, be inferred from surface marker expression in combination with functional analysis [16]. Similar strategies have been applied to identify the primitive neural cells. For example, cells with CD133+CD34-CD45-CD24- phenotype represent the neural stem/progenitor cells from embryonic human brain tissues [17]. Neuronal lineage restricted precursors can be isolated via E-NCAM expression [18], [19]. Along the glial lineage, the neural stem cell derived immediate progeny are likely the A2B5 expressing glial-restricted precursor (GRP), which are capable of generating oligodendrocytes, type-2 astrocytes and type-1 astrocytes [20], [21]. Other types of glial lineage progenitor cells, likely downstream to GRP, have also been identified via A2B5 expression [20]-[27]. Although the exact in vivo relationship between these A2B5 expressing glial precursors has been challenging to establish, in vitro studies have demonstrated that GRP can generate oligodendrocyte/type-2 astrocyte progenitor (O-2A) cells and type-1 astrocyte-restricted progenitor (ARP) [21], [28]. The O-2A progenitor cells, which are characterized by cell surface expression of platelet-derived growth factor receptor-alpha (PDGFRalpha), A2B5 and O4, can account for 4% of the adult human white matter cells [22], [25], [26]. Via early and late oligodendrocyte progenitors, which gradually lose PDGFRalpha, A2B5 and O4 expression and gain O1 expression in pre-myelinating oligodendrocytes, O-2A progenitor cells give rise to oligodendrocytes [21], [27], [29]. But O-2A progenitor cells can in vitro also give rise to type-2 astrocytes in a growth factor cue dependent manner [26]. Depending on the utility of growth factor combinations, O-2A progenitor cells can also be reprogrammed to acquire neurosphere-forming and neuronal lineage differentiation capacities [11]. The ARPs also express A2B5, but not PDGFRalpha and O4 [22]-[24], [29]. Human ARPs were also demonstrated to express CD44 [28], [30].
###end p 11
###begin p 12
###xml 488 492 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Bonnet1">[31]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Castor1">[32]</xref>
###xml 833 840 833 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 743 750 <span type="species:ncbi:9606">patient</span>
As demonstrated in previous studies, although gene expression of cancer cells reflects genetic and epigenetic alterations, a considerable fraction of this gene expression can nevertheless be characteristic of the non-transformed cell-of-origin. This principle has been applied to distinguish between leukemias originating from either stem cells or from progenitor cells by characterization of cancer initiating capacity and cancer-characteristic genetic mutations in these cell fractions [31], [32]. In this study, we characterized freshly isolated low-grade and high-grade glioma cells for expression of surface markers characteristic of the glial lineage differentiation hierarchy and analyzed the expression of these markers in relation to patient survival. We also studied the glioma cell multi-lineage differentiation potential in vivo by assessing GFAP and NSE/synaptophysin expression in the corresponding formaldehyde fixed specimens.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Tumor specimens, cell processing and flow cytometric analysis
###end title 14
###begin p 15
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 315 322 <span type="species:ncbi:9606">Patient</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
Glioma biopsies of fresh tumor tissue were obtained from patients operated at the Clinic of Neurosurgery, Lund University Hospital, Sweden. Formaldehyde-fixed, paraffin embedded tissue blocks derived from the same surgical excision biopsies were obtained from the Department of Pathology, Lund University Hospital. Patient survival data were obtained from the Swedish National Register of Population (National Board of Health and Welfare). Permission for using these materials was obtained from The Regional Ethical Review Board in Lund, and written informed consent was obtained from patients.
###end p 15
###begin p 16
###xml 236 237 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 480 481 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 673 674 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1379 1381 1337 1339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2a</sub>
###xml 570 575 <span type="species:ncbi:10090">mouse</span>
###xml 1342 1345 <span type="species:ncbi:10116">rat</span>
###xml 1351 1356 <span type="species:ncbi:10090">mouse</span>
###xml 1368 1371 <span type="species:ncbi:10116">Rat</span>
For preparing viable glioma cells, freshly obtained specimen were cut finely into small pieces, treated in IMDM with 0.5 mg/ml collagenase (Sigma) and 25 microg/ml DNAse (Sigma) at 37degreesC for 40 minutes. Red cells were lysed with NH4Cl; the resulting cells were washed in PBS containing 2% FCS. For flow-cytometry analysis, these cells were either used directly or resuspended in freezing medium containing 10% DMSO and 90% FCS for storage in liquid nitrogen. About 5 to 10x106 of the freshly isolated or thawed cells were first incubated with non-specific blocking mouse IgG1 at 50 microg/ml (clone MOPC 21, Sigma) at 4degreesC for 20 minutes. Subsequently, about 5x105 cells were stained with allophycocyanin (APC)-conjugated anti-CD45 (clone 2D1), anti-CD31 (clone AC114.5) monoclonal antibodies (mAb) in combination with one of the fluorescein isothiocyanate or phycoerythrin (PE)-conjugated mAbs against PDGFRalpha (clone alphaR1), CD44 (clone G44-26), CD24 (clone ML5), EGFR (clone EGFR1) or CD133 (clone AC133), or the isotype-matched control mAbs, at saturating concentrations at 4degreesC for 15 minutes. Subsequently, cells were washed once with PBS and resuspended in 500 microl PBS supplemented with 2% FCS and 1.0 microg/ml 7-aminoactinomycin D (7-AAD, Sigma). The A2B5, O4, and O1 staining were detected using PE-conjugated rat-anti-mouse-IgM (clone Rat(LOU)IgG2a) and a staining omitting the unconjugated primary mAb served as control. The multiparameter flow cytometric analysis was performed in a FACScalibur. At least 50 000 events were counted and cell surface expression was analyzed in 7-AAD negatively stained living cells using the Cellquest or Flowjo program. PE-conjugated anti-CD133 and APC-conjugated anti-CD31 mAbs were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany) and unconjugated anti-A2B5 (MAB312R), O4 (MAB345), and O1 mAb (MAB1327) from Chemicon Europe, Ltd. (Hampshire, UK). All other mAbs were purchased from BD Biosciences Immunocytometry Systems. The flow-cytometry analysis was performed at least twice for most of the specimens when sufficient cells were available. CD133 expression was analyzed with two batches of anti-CD133 mAb with comparable data.
###end p 16
###begin title 17
Karyotype analysis of short-term cultured glioma cells
###end title 17
###begin p 18
###xml 100 104 <span type="species:ncbi:9913">calf</span>
Freshly isolated or thawed glioma cells were cultured in DMDM/F12 medium supplemented with 2% fetal calf serum, basic fibroblast growth factor (20 ng/ml), platelet derived growth factor-AA (20 ng/ml), sonic hedgehoge (2 ng/ml) and 1xN2.
###end p 18
###begin p 19
Chromosome banding analysis was performed between passage 3 to 4 by standard methods.
###end p 19
###begin title 20
Immunohistochemistry analysis
###end title 20
###begin p 21
Sections of five-microm thickness were mounted on capillary glass slides (DAKO ChemMate Capillary Gap Microscope Slides, 75 mm, DAKO Sweden AB). All sections were microwave pre-treated in 10 mM citrate buffer pH 6.0 for 15 minutes at 800 W in order to achieve antigen retrieval. An automated immunostainer (TechMateTM 500 Plus, DAKO Sweden AB) was used for the staining procedure using DAKO ChemMate Kit Peroxidase/3-3'diaminobenzidine. Primary antibodies used were GFAP (DAKO, polyclonal, 1:5000 dilution), NSE (Zymed, clone NSE-1G4, 1:1500 dilution) and synaptophysin (DAKO, polyclonal, 1:100 dilution). Staining was semi-quantitatively evaluated for the proportion of positively stained versus total cell numbers and the extent of staining intensity. These two variables generally co-vary between samples. The staining was judged as either markedly positive (++), low-moderately positive (+) or negative (-).
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 110 114 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Uchida1">[17]</xref>
###xml 116 120 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Rao1">[20]</xref>
###xml 121 125 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Scolding2">[24]</xref>
###xml 127 131 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Dietrich1">[27]</xref>
###xml 132 136 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Alfei1">[30]</xref>
###xml 163 166 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Singh1">[7]</xref>
###xml 168 172 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Uchida1">[17]</xref>
###xml 373 377 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kornblum1">[33]</xref>
###xml 444 448 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Frederick1">[34]</xref>
###xml 591 599 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g001">Figure 1</xref>
###xml 910 917 902 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Table 1</xref>
###xml 1022 1029 1014 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">Table 2</xref>
###xml 1034 1042 1026 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 1233 1234 1225 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1601 1605 1593 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Uchida1">[17]</xref>
###xml 1607 1611 1599 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Cai1">[35]</xref>
###xml 1612 1616 1604 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Tamaki1">[38]</xref>
We have analyzed the expression of PDGFRalpha, A2B5, O4 and CD44 as surface markers for glial precursor cells [17], [20]-[24], [27]-[30], and CD133 for stem cells [7], [17] on freshly prepared glioma cells using flow cytometry. In addition, we analyzed the expression of EGFR, which is expressed in immature astrocytes and is critically important for astrocyte development [33]. EGFR is also frequently overexpressed in high-grade glioma cells [34]. Six low-grade and 17 high-grade glioma specimens were analyzed. As shown by representative dot-plot profiles for low-grade glioma specimens (Figure 1), intermingled cells of hematopoietic origin can be distinguished via their CD45 expression. PDGFRalpha, A2B5, O4, and CD44 were found to be expressed in nearly all CD45 negative cells. The concomitant expression of these progenitor cell markers was observed in nearly all low-grade glioma specimens analyzed (Table 1). These data, combined with the homogenous GFAP staining and the absence of NSE/synaptophysin staining (Table 2 and Figure 2), suggest that low-grade glioma cells are reminiscent of glial-progenitor cells. In 4 out of 6 low-grade glioma specimens, CD133 expression was observed at lower frequencies, but these CD133+ cells are predominantly of blood vessel endothelial origin (see below). The expression of EGFR was found in specimens from 2 of the 6 low-grade gliomas. We also analyzed the expression of CD24. Absence of CD24 expression in combination with positive staining on CD133, or PNA or ABCG2/Bcrp1 was used to enrich primitive neural cells with "stem cell-like" properties [17], [35]-[38]. CD24 expression was detected in 4 out of 6 low-grade gliomas.
###end p 23
###begin title 24
###xml 98 103 <span type="species:ncbi:9606">human</span>
Low-grade glioma cells concurrently express multiple cell surface markers characteristic of adult human glial progenitors.
###end title 24
###begin p 25
###xml 130 138 <span type="species:ncbi:9606">patients</span>
Dot-plot profiles of glial progenitor cell surface markers and CD133 expression on low-grade glioma cells from two representative patients (#1 (A) and #4 (B)) are shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were distinguished with anti-CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.
###end p 25
###begin title 26
Neuronal marker expression was not detected in low-grade gliomas, but in high-grade gliomas.
###end title 26
###begin p 27
###xml 77 84 <span type="species:ncbi:9606">patient</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
Staining patterns of GFAP and NSE expression from representative low-glioma (patient ID: #2) and high-grade glioma ((patient ID: #12 and #19) are shown. Original magnification: x100
###end p 27
###begin title 28
Expression of neural stem cell and glial progenitor surface markers in low- and high-grade glioma specimens analyzed.
###end title 28
###begin p 29
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
###xml 427 430 <span type="species:ncbi:10116">rat</span>
###xml 436 441 <span type="species:ncbi:10090">mouse</span>
Freshly prepared or thawed glioma cells were first incubated with non-specific mouse IgG1 mAb, cells were subsequently incubated with APC conjugated anti-CD45 mAb in combination with FITC conjugated anti-CD44, or anti-CD24 mAbs or PE conjugated anti-PDGFRalpha, anti-EGFR, anti-CD133 mAbs. For A2B5 and O4 staining, cells were incubated with unconjugated A2B5 or O4 mAb respectively and subsequently stained with PE conjugated rat anti-mouse IgM. Cells negatively stained with 7-AAD were analyzed for cell surface marker expression. Data shown are the percentages of CD45 negative cells positively stained for indicated cell surface markers.
###end p 29
###begin p 30
: secondary GBM. UD: undetectable; ND: not done. PNET: primitive neuroectodermal tumor.
###end p 30
###begin title 31
Co-expression of neuronal and glial markers in high-grade glioma cells
###end title 31
###begin p 32
The GFAP and NSE staining was performed in the fixed glioma specimens from the same surgical procedures as those used for generating viable cells. The staining was semi-quantitatively evaluated. +++: markedly positive staining; ++: moderately positive staining; +: low positive; -: no positive staining in the tumor.
###end p 32
###begin p 33
###xml 148 155 144 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Table 1</xref>
###xml 160 168 156 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g003">Figure 3</xref>
###xml 285 292 281 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">Table 2</xref>
###xml 297 305 293 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 537 538 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 852 859 848 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 884 891 880 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Table 1</xref>
###xml 825 833 <span type="species:ncbi:9606">patients</span>
As in low-grade glioma cells, high-grade glioma cells analyzed in this study maintained the expression profiles for PDGFRalpha, A2B5, O4 and CD44 ( Table 1 and Figure 3). In all these high-grade glioma cases, GFAP expression was detected with inter- as well as intra-glioma variation (Table 2 and Figure 2). The expression of CD24 was observed in 7 of 16 high-grade gliomas analyzed. In striking contrast to the low-grade glioma cells, distinct cell populations with high intensity of CD133 expression (ranging from 22 to 90% of the CD45- cell fraction) was detected in 12 of the 17 high-grade glioma specimens. In addition, EGFR over-expression was detected in 11 of the 17 high-grade glioma specimens analyzed. Of note, no detectable difference in cell surface marker expression profile was observed between the secondary (patients ID 15 and 16) and de novo GBM specimens analyzed (Table 1).
###end p 33
###begin title 34
Maintenance of glial progenitor-like phenotype, but enhanced CD133 expression in high-grade gliomas.
###end title 34
###begin p 35
###xml 293 301 <span type="species:ncbi:9606">patients</span>
In addition to multiple glial progenitor cell markers, a high proportion of glioma cells co-expressing CD133 was detected in most of the high-grade glioma specimens. Dot-plot profiles of glial progenitor cell surface markers and CD133 expression on high-grade glioma cells from representative patients (#14 (A) and #22 (B)) are shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were distinguished with anti-CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.
###end p 35
###begin p 36
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Urbich1">[39]</xref>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 523 527 523 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Baeten1">[40]</xref>
###xml 541 549 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g004">Figure 4</xref>
###xml 577 578 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 589 590 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 735 736 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 741 742 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 772 773 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 888 889 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1076 1077 1076 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1120 1121 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1126 1127 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
As gliomas, particularly the high-grade gliomas, are highly vascularized, newly formed blood vessel endothelial cells may also express CD133 [39]. To ascertain the glioma origin of the CD133+ cell fraction in our low-grade and high-grade glioma specimens, we subsequently performed CD133 expression analysis in combination with CD45 and CD31 staining. By doing so, it is possible to distinguish glioma cells from both hematopoietic cells (via CD45 expression) and tumor blood vessel endothelial cells (via CD31 expression) [40]. As shown in Figure 4, a small population of CD45-, but CD133+ cells can be detected in low-grade glioma specimens. Relatively higher frequencies of such cells were found in GBM specimens. However, such CD45-CD133+ cells were predominantly CD31+ in low-grade glioma specimens (ranging from 0.3 to 7% of the total living cells, n = 4). This indicates that CD133+ cells, if present in low-grade gliomas, are predominantly derived from newly formed blood vessel endothelial cells, and not from the glioma cells. In GBM specimens, the majority of CD133+ cells were of glioma origin, although CD31+CD133+ cells (ranging from 0.5 to 10% of the total living cells, n = 9) were also found.
###end p 36
###begin title 37
Vessel or glioma origin of CD133 expressing cells.
###end title 37
###begin p 38
###xml 286 294 <span type="species:ncbi:9606">patients</span>
In contrast to high-grade glioma specimens, CD133 expressing cells detected in low-grade glioma specimens are predominantly derived from blood vessel endothelial cells. Dot-plot profiles of CD133 expression versus CD45 and/or CD31 expression of cells from glioma specimens of indicated patients are shown. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.
###end p 38
###begin p 39
###xml 155 158 155 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Bouvier1">[1]</xref>
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Shoshan1">[3]</xref>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Rao1">[20]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Dietrich1">[27]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Wolswijk1">[41]</xref>
###xml 361 365 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Sim1">[22]</xref>
###xml 367 371 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Roy1">[25]</xref>
###xml 373 377 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Raff1">[26]</xref>
###xml 379 383 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Pringle1">[42]</xref>
###xml 384 388 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Ellison1">[44]</xref>
###xml 449 453 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Armstrong1">[29]</xref>
###xml 810 814 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Armstrong1">[29]</xref>
###xml 889 890 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 988 995 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Table 1</xref>
###xml 1000 1008 996 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g005">Figure 5</xref>
###xml 1166 1167 1162 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1178 1179 1170 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In agreement with previous studies demonstrating glioma expression of oligodendrocyte progenitor cell transcription factor Olig1/2 and surface antigen NG2 [1]-[3], the concomitant expression of A2B5 (a marker for multiple types of progenitor cells in glial lineage [20]-[27], [41]), PDGFRalpha (a marker for early oligodendrocyte progenitor cells at O-2A stage [22], [25], [26], [42]-[44]) and O4 (a marker for late oligodendrocyte progenitor cells [29]) suggests that glioma cells, irrespective of their morphological characteristics, are committed to the oligodendrocyte lineage. To further characterize the differentiation stages along the oligodendrocyte lineage downstream of the A2B5 expressing glial progenitor cell level, we analyzed the expression of O1, a marker for pre-myelinating oligodendrocytes [29]. In contrast to the high level A2B5 and O4 expression, the frequency of O1+ cells were significantly diminished in all low-grade and the majority of GBM specimens analyzed (Table 1 and Figure 5). The expression of GFAP and these oligodendrocyte progenitor surface markers suggests that along the oligodendrocyte lineage differentiation hierarchy, A2B5+/PDGFRalpha+ glioma cells were compromised in differentiation downstream of A2B5/O4, but upstream of the O1 stage.
###end p 39
###begin title 40
Glioma cells are compromised in downstream differentiation at the O4 stage.
###end title 40
###begin p 41
###xml 181 182 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 192 193 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 290 297 <span type="species:ncbi:9606">patient</span>
###xml 314 321 <span type="species:ncbi:9606">patient</span>
Glioma cells were stained with APC conjugated anti-CD45 and anti-CD31 mAbs in combination with staining for A2B5, or O4 or O1. Data shown are the ratio of the percentages between O4+/CD45-CD31- and A2B5+/CD45-CD31- phenotype or between O1+/CD45-CD31- and A2B5+/CD45-CD31- phenotype in each patient. The ependymoma patient was not included in this analysis.
###end p 41
###begin p 42
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">Table 2</xref>
###xml 208 216 208 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 346 353 346 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">Table 2</xref>
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 507 515 507 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 618 625 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">Table 2</xref>
###xml 630 638 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">Figure 2</xref>
###xml 906 914 906 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Tables 1</xref>
###xml 919 920 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t002">2</xref>
###xml 922 931 922 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g001">Figures 1</xref>
###xml 933 934 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g002">2</xref>
###xml 939 940 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g003">3</xref>
To study glioma cell differentiation potential along neuronal lineage, we performed an immunohistochemical staining for pan-neuronal marker NSE and synaptophysin expression in archival specimens (Table 2 and Figure 2). In low-grade gliomas, no obvious expression of NSE and synaptophysin was detected, but the cells homogeneously expressed GFAP (Table 2 and Figure 2). We were unable to ascertain whether the few cells weakly stained for NSE were the intermingled normal neuronal cells or the glioma cells (Figure 2, upper panel). In high-grade glioma cells, a regional NSE expression was clear in all cases analyzed (Table 2 and Figure 2), although both region-dependent and homogeneous expression patterns were detected. Synaptophysin positivity was detected in 7 high-grade gliomas. These data, in combination with the expression of GFAP and multiple oligodendrocyte lineage progenitor surface markers (Tables 1 and 2, Figures 1, 2 and 3), suggest that compared to low-grade glioma cells, high-grade glioma cells maintain glial progenitor-like features, but additionally exhibit enhanced CD133 expression as well as neuronal differentiation potential.
###end p 42
###begin p 43
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Assanah1">[45]</xref>
###xml 319 326 319 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t003">Table 3</xref>
###xml 713 722 713 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g001">Figures 1</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g003">3</xref>
###xml 980 984 980 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Glanz1">[46]</xref>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
###xml 549 556 <span type="species:ncbi:9606">patient</span>
###xml 581 588 <span type="species:ncbi:9606">patient</span>
###xml 772 780 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
Transformed glial progenitor-like cells can provide a niche environment recruiting normal stem cells or progenitor cells into the tumor mass [45]. To investigate whether freshly isolated glioma cells studied here indeed contained transformed cells, karyotype analysis was performed in short-term cultured glioma cells (Table 3). We only observed normal karyotype for cells derived from patients 3 and 8. Abnormal karyotypes were observed from cells derived from patients 4, 12, 13, 14, 17, 18 and 20. Of note, cultures derived from low-grade glioma patient 4 and high-grade glioma patient 12 contained about 40% of the cells with a normal karyotype, contrasting the nearly homogenous phenotype between all cells (Figures 1, 3); but cultures derived from high-grade glioma patients 13, 14, 17, 18 and 20 predominantly contained cells with abnormal karyotypes. In addition, fresh cells from patients 14 and 20 formed xenograft glioma following subcutaneous injection into SCID mice [46]. Thus, the analyzed glioma cells did contain neoplastic cells and the karyotype normal and abnormal glioma cells showed hitherto indistinguishable phenotype.
###end p 43
###begin title 44
Karyotype analysis of short-term cultured glioma cells
###end title 44
###begin p 45
Freshly isolated glioma cells were cultured and analyzed for karyotype between passage 3 to 4. The number in brackets represents the number of the indicated karyotype.
###end p 45
###begin p 46
###xml 369 370 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 503 504 503 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 607 608 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 621 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 631 632 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 639 647 635 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001936-g006">Figure 6</xref>
###xml 139 146 <span type="species:ncbi:9606">patient</span>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 706 713 <span type="species:ncbi:9606">patient</span>
Finally, we investigated whether the glial progenitor or stem cell markers expressed on glioma cells could serve as prognostic markers for patient survival. Glioblastoma patients receiving immune therapy and patients with pilocytic astrocytoma or ependymoma, were excluded from the prognosis analysis. We divided all analyzed grade II to IV glioma patients into a CD133+ low group (CD133+ cells less than 30%) and a CD133+ high group (CD133+ cells higher than 30%). The median survival time in the CD133+ high group was 5.0+/-9.2 months (n = 9) compared to more than 22.0+/-17.3 months (n = 10) in the CD133+ low group (P = 0.026, t test; Figure 6). Thus, CD133 expression inversely correlates with glioma patient survival time.
###end p 46
###begin title 47
###xml 65 72 <span type="species:ncbi:9606">patient</span>
CD133 expression correlates inversely with grade II to IV glioma patient survival time.
###end title 47
###begin p 48
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 160 167 <span type="species:ncbi:9606">patient</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
The survival time calculated from the day of operation was plotted against the percentage of CD133+ cells in the CD45- cell fraction from the specimens of each patient. UD: undetectable CD133 expression. Bold black bars indicate the median survival time for patients in groups with CD133+ cells either lower or higher than 30% of total CD45- cells.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 1127 1128 1123 1124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1214 1215 1210 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1267 1268 1263 1264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1490 1497 1486 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 1567 1574 <span type="species:ncbi:9606">patient</span>
In this study, we investigated the expression of multiple cell surface markers characteristic of glial genesis hierarchy in freshly isolated viable glioma cells as well as the expression of GFAP, NSE and synaptophysin in the fixed specimens from a cohort of low-grade and high-grade glioma patients. Our data show that nearly all low-grade glioma cells from the analyzed cases concomitantly express multiple cell surface markers for glial progenitor cells, such as PDGFRalpha, A2B5, O4, and CD44. The expression of these glial progenitor markers is maintained in the high-grade gliomas analyzed. GFAP expression was detected, as anticipated, in all low- and high-grade gliomas analyzed, but the expression of NSE and synaptophysin was only detected in high-grade gliomas. Co-staining of CD31 suggests that the rare CD133 expressing cells in low-grade gliomas are predominantly of vessel endothelial origin. In more than 50% of the high-grade glioma cases, distinct CD133 expression was detected in cells concomitantly expressing multiple glial progenitor markers. Thus, low-grade glioma cells may resemble the expansion of A2B5+ glial progenitor-like cells; high-grade gliomas, in addition to the expansion of A2B5+ glial progenitor-like cells, may also contain CD133+ putative glioma stem cells that concomitantly express multiple surface markers of glial progenitor cells. Irrespective of CD133 expression, high-grade glioma cells are endowed with multi-lineage differentiation potential in vivo. Importantly, CD133 expression negatively correlated with the glioma patient survival time.
###end p 50
###begin p 51
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kho1">[47]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Holland1">[48]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu2">[49]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Sanai1">[50]</xref>
###xml 694 698 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Scolding2">[24]</xref>
###xml 700 704 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Roy1">[25]</xref>
###xml 706 710 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Wolswijk1">[41]</xref>
###xml 712 716 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Zhang1">[51]</xref>
###xml 717 721 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Nunes1">[53]</xref>
###xml 746 747 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 749 750 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 760 761 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 775 776 767 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 778 779 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 789 790 777 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 794 795 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1138 1139 1122 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1148 1149 1132 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1159 1163 1143 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Xia1">[54]</xref>
###xml 1165 1169 1149 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Bishop1">[55]</xref>
###xml 1821 1824 1801 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Bouvier1">[1]</xref>
###xml 1825 1828 1805 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Shoshan1">[3]</xref>
###xml 2381 2385 2361 2365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Rao1">[20]</xref>
###xml 2387 2391 2367 2371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Gregori1">[21]</xref>
###xml 2393 2397 2373 2377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu1">[28]</xref>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
Conserved mechanisms across organ development/homeostasis and tumorigenesis have been demonstrated in many types of human cancers [47]. It is likely that gliomas may originate from the primitive cells along the postnatal glial genesis hierarchy. In fact, glial progenitor cells were demonstrated to be more susceptible to oncogene transformation compared to mature astrocytes [48]. Glial genesis originates from neural stem cells via multiple types of intermediate glial precursors [49]. In adult human CNS, putative neural stem cells have been identified in restricted brain regions [50]. In contrast, A2B5 and PDGFRalpha expressing O-2A progenitors are relatively abundant throughout the CNS [24], [25], [41], [51]-[53]. The aforementioned A2B5+O4-PDGFRalpha- GRPs and A2B5+O4-PDGFRalpha-CD44+ ARPs may also exist. In addition to well-established PDGFRalpha expression, we identified that the majority of low-grade astrocytomas and high-grade gliomas concomitantly express multiple markers of glial progenitor cells such as A2B5 and O4. Our findings seem not consistent with previous reports that astrocytomas could be divided into A2B5+ and A2B5- lineages [54], [55]. This discrepancy is likely caused by the fact that the eiptopes recognized by the A2B5, O4 and O1 antibodies are not well maintained in formalin fixed, paraffin embedded specimens, and our studies were performed in living glioma cells. It is unlikely that the co-expression of these cell surface markers is a consequence of a cell type dependent/independent program inherent to all glioma cells, rather it reflects the differentiation stage(s) common to normal glial genesis hierarchy and glioma cells. In line with previous reports identifying oligodendroglial lineage markers such as Olig2 or NG2/PDGFRalpha as universal markers in diffuse gliomas [1]-[3], our study demonstrates the shared pattern of concomitant expression of multiple surface markers between glioma cells and oligodendrocyte progenitor cells, which suggests that most of the morphologically diagnosed astrocytoma and GBM are endowed with oligodendrocyte lineage differentiation potential. The data of weak O1 expression, but homogenous GFAP expression, indicate that these cells are likely blocked at differentiation pathways between O4 and O1 stages in oligodendrocyte lineage or at hitherto unidentified stages towards type-2 astrocytes [20], [21], [28].
###end p 51
###begin p 52
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu1">[28]</xref>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 202 203 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 205 206 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 428 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Liu1">[28]</xref>
###xml 470 471 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 475 476 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 559 566 551 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001936-t001">Table 1</xref>
The expression of CD44 identifies the ARPs [28] and nearly all gliomas express this marker. This CD44 expression does not necessarily contradict the oligodendrocyte lineage commitment of A2B5+PDGFRalpha+O4+ glioma cells which exhibited a concomitant GFAP expression, because a misexpression of CD44 can result in expansion of oligodendrocyte progenitor cells with impaired maturation and concomitant gain of GFAP expression [28]. However, it cannot be excluded that A2B5+CD44+GFAP+ glioma cells without detectable PDGFRalpha and O4 expression (e.g.: case #9, Table 1) actually represent the expansion of ARP-like cells.
###end p 52
###begin p 53
###xml 139 142 139 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Hemmati1">[8]</xref>
###xml 144 147 144 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Galli1">[9]</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Singh2">[56]</xref>
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Yuan1">[57]</xref>
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Reynolds1">[10]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Kondo1">[11]</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Gabay1">[58]</xref>
###xml 896 903 896 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 937 944 937 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1059 1066 1059 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Previous neurosphere culture-based studies have demonstrated that sphere-forming glioma cells are capable of multi-lineage differentiation [8], [9], [56], [57]. A potential inherent weakness in this type of studies, however, is that neurosphere culture studies only assess the particular fractions of glioma cells, which are supported by the neurosphere culture conditions [10], and the neurosphere culture conditions do not necessarily represent the glioma niche environment. Additionally, multi-lineage differentiation capacity can also reflect the differentiation plasticity induced by neurosphere culture conditions. It has been demonstrated that lineage-restricted progenitors gain multi-lineage differentiation capacity in neurosphere-forming assay [11], [58]. We demonstrate that high-grade glioma cells, in contrast to low-grade glioma cells, can express neuronal marker as well as CD133 in vivo. Thus, our data suggest that the in vivo multi-lineage differentiation capacity is likely restricted to high-grade glioma cells. It is unclear whether the in vivo multi-lineage differentiation capacity can be gained following the progression from low-grade to high-grade gliomas.
###end p 53
###begin p 54
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Assanah1">[45]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Assanah1">[45]</xref>
###xml 214 219 <span type="species:ncbi:10090">mouse</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
Gliomas are composed of a mixture of neoplastic and non-neoplastic cells [45]. The non-neoplastic cells could include entrapped neurons, astrocytes, microglial cells, blood vessel cells. It is also demonstrated in mouse glioma models that normal progenitor or stem cells can be recruited to glioma niche [45]. Although the possibility could not be entirely excluded that the cells with normal karyotype or isolated numerical aberrations are also neoplastic, our data suggest that most of the entrapped cells in human gliomas show a progenitor or stem cell-like phenotype and such cells can constitute more than 40% of the total cells in low-grade gliomas, but their frequency varies substantially in GBM specimens. It remains to be established whether neoplastic and non-neoplastic cells in gliomas can be phenotypically distinguished.
###end p 54
###begin p 55
###xml 574 578 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Glinsky1">[59]</xref>
###xml 580 584 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Taubert1">[60]</xref>
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Zeppernick1">[61]</xref>
###xml 1013 1016 1013 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Singh1">[7]</xref>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Singh2">[56]</xref>
###xml 1024 1028 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001936-Zeppernick1">[61]</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
Considering gliomas as a group of progressive tumors, our data demonstrate that expression of the CD133 associated stem cell features is correlated with a poor prognosis. High-grade glioma patients without detectable frequencies of CD133 expressing cells as well as grade II glioma patients appeared to survive significantly longer compared to high-grade glioma patients with high frequencies of CD133 expressing glioma cells. This finding extends previous studies that "stem cell-ness" gene expression pattern can serve as a marker for poor prognosis of malignant diseases [59], [60]. Our findings are consistent with a recent report on a correlation between enhanced CD133 expression and a poor clinical outcome in glioma patients [61]. Importantly, we show that the rare CD133 expressing cells in low-grade gliomas are predominantly of blood vessel origin. Of note, the frequencies of CD133 expressing cells in high-grade gliomas analyzed in our studies appeared to be much higher compared to previous reports [7], [56], [61]. This discrepancy could be because we analyzed the CD133 expressing cells in CD45-negative cell fraction and glioma specimens can have different contents of hematopoietic cells.
###end p 55
###begin p 56
This study constitutes an important step towards clarifying the lineage commitment and differentiation blockage of glioma cells. We have demonstrated that normal glial progenitor cell surface markers are widely expressed in glioma cells. Glial progenitor cell surface markers could potentially be used to design glial progenitor antigen-targeted immune therapy or gene therapy. As normal neural stem cells are believed to be devoid of glial progenitor cell surface markers, targeted delivery of cytotoxic agents to selectively ablate glioma cells would spare the normal neural stem cells.
###end p 56
###begin p 57
###xml 252 259 <span type="species:ncbi:9606">patient</span>
We thank Anders Bjorklund, Perrine Barraud, Ulrike Nuber for insightful discussions and valuable support for this study. Monika Andersson and the staff at the Department of Neurosurgery, Lund University Hospital are thanked for specimen collection and patient information. Christine Glanz is thanked for work in the early stage of this project. Seema Rosqvist and Hans Olov Sjogren are particularly thanked for critical reading of the manuscript. Xiaolong Fan is a Li Ka Shing Scholar.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
###end article-title 59
###begin article-title 60
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
###end article-title 60
###begin article-title 61
Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors.
###end article-title 61
###begin article-title 62
Glioma classification: a molecular reappraisal.
###end article-title 62
###begin article-title 63
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
###end article-title 63
###begin article-title 64
Angiogenesis-independent tumor growth mediated by stem-like cancer cells.
###end article-title 64
###begin article-title 65
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells.
###end article-title 65
###begin article-title 66
Cancerous stem cells can arise from pediatric brain tumors.
###end article-title 66
###begin article-title 67
###xml 80 85 <span type="species:ncbi:9606">human</span>
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.
###end article-title 67
###begin article-title 68
Neural stem cells and neurospheres--re-evaluating the relationship.
###end article-title 68
###begin article-title 69
Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells.
###end article-title 69
###begin article-title 70
Identifying cancer stem cells in solid tumors: case not proven.
###end article-title 70
###begin article-title 71
Tumor growth need not be driven by rare cancer stem cells.
###end article-title 71
###begin article-title 72
Glioma stem cells: Evidence and limitation.
###end article-title 72
###begin article-title 73
The development of neural stem cells.
###end article-title 73
###begin article-title 74
Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations.
###end article-title 74
###begin article-title 75
###xml 20 25 <span type="species:ncbi:9606">human</span>
Direct isolation of human central nervous system stem cells.
###end article-title 75
###begin article-title 76
Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells.
###end article-title 76
###begin article-title 77
###xml 82 87 <span type="species:ncbi:9606">human</span>
Identification and characterization of neuronal precursors and their progeny from human fetal tissue.
###end article-title 77
###begin article-title 78
A tripotential glial precursor cell is present in the developing spinal cord.
###end article-title 78
###begin article-title 79
The tripotential glial-restricted precursor (GRP) cell and glial development in the spinal cord: generation of bipotential oligodendrocyte-type-2 astrocyte progenitor cells and dorsal-ventral differences in GRP cell function.
###end article-title 79
###begin article-title 80
###xml 45 50 <span type="species:ncbi:9606">human</span>
Complementary patterns of gene expression by human oligodendrocyte progenitors and their environment predict determinants of progenitor maintenance and differentiation.
###end article-title 80
###begin article-title 81
###xml 112 117 <span type="species:ncbi:9606">human</span>
Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter.
###end article-title 81
###begin article-title 82
###xml 60 65 <span type="species:ncbi:9606">human</span>
Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis.
###end article-title 82
###begin article-title 83
###xml 118 123 <span type="species:ncbi:9606">human</span>
Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter.
###end article-title 83
###begin article-title 84
A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium.
###end article-title 84
###begin article-title 85
###xml 67 72 <span type="species:ncbi:9606">human</span>
Characterization of A2B5+ glial precursor cells from cryopreserved human fetal brain progenitor cells.
###end article-title 85
###begin article-title 86
CD44 expression identifies astrocyte-restricted precursor cells.
###end article-title 86
###begin article-title 87
###xml 32 37 <span type="species:ncbi:9606">human</span>
Pre-oligodendrocytes from adult human CNS.
###end article-title 87
###begin article-title 88
###xml 66 73 <span type="species:ncbi:9031">chicken</span>
###xml 135 140 <span type="species:ncbi:9031">chick</span>
Hyaluronate receptor CD44 is expressed by astrocytes in the adult chicken and in astrocyte cell precursors in early development of the chick spinal cord.
###end article-title 88
###begin article-title 89
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.
###end article-title 89
###begin article-title 90
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
###end article-title 90
###begin article-title 91
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor.
###end article-title 91
###begin article-title 92
###xml 73 78 <span type="species:ncbi:9606">human</span>
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
###end article-title 92
###begin article-title 93
###xml 23 26 <span type="species:ncbi:10116">rat</span>
Membrane properties of rat embryonic multipotent neural stem cells.
###end article-title 93
###begin article-title 94
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.
###end article-title 94
###begin article-title 95
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Flow cytometric analysis of neural stem cells in the developing and adult mouse brain.
###end article-title 95
###begin article-title 96
###xml 31 36 <span type="species:ncbi:9606">human</span>
Engraftment of sorted/expanded human central nervous system stem cells from fetal brain.
###end article-title 96
###begin article-title 97
Endothelial progenitor cells: characterization and role in vascular biology.
###end article-title 97
###begin article-title 98
Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment.
###end article-title 98
###begin article-title 99
Identification of an adult-specific glial progenitor cell.
###end article-title 99
###begin article-title 100
A singularity of PDGF alpha-receptor expression in the dorsoventral axis of the neural tube may define the origin of the oligodendrocyte lineage.
###end article-title 100
###begin article-title 101
###xml 22 25 <span type="species:ncbi:10116">rat</span>
PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage.
###end article-title 101
###begin article-title 102
Platelet-derived growth factor receptor is expressed by cells in the early oligodendrocyte lineage.
###end article-title 102
###begin article-title 103
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.
###end article-title 103
###begin article-title 104
Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability.
###end article-title 104
###begin article-title 105
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers.
###end article-title 105
###begin article-title 106
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.
###end article-title 106
###begin article-title 107
Glial progenitors in the CNS and possible lineage relationships among them.
###end article-title 107
###begin article-title 108
###xml 33 38 <span type="species:ncbi:9606">human</span>
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration.
###end article-title 108
###begin article-title 109
Adult brain retains the potential to generate oligodendroglial progenitors with extensive myelination capacity.
###end article-title 109
###begin article-title 110
Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.
###end article-title 110
###begin article-title 111
###xml 118 123 <span type="species:ncbi:9606">human</span>
Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain.
###end article-title 111
###begin article-title 112
###xml 17 22 <span type="species:ncbi:9606">human</span>
A2B5 lineages of human astrocytic tumors and their recurrence.
###end article-title 112
###begin article-title 113
Dual lineage of astrocytomas.
###end article-title 113
###begin article-title 114
###xml 40 45 <span type="species:ncbi:9606">human</span>
Identification of a cancer stem cell in human brain tumors.
###end article-title 114
###begin article-title 115
Isolation of cancer stem cells from adult glioblastoma multiforme.
###end article-title 115
###begin article-title 116
Deregulation of dorsoventral patterning by FGF confers trilineage differentiation capacity on CNS stem cells in vitro.
###end article-title 116
###begin article-title 117
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
###end article-title 117
###begin article-title 118
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients.
###end article-title 118
###begin article-title 119
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by the Swedish Cancer Society, the Swedish Pediatric Cancer Foundation, The Swedish Research Council, Lund University Medical Faculty, Hans and Marit Rausing charitable foundation, VFK Krebsforschung gGmbH and Gunnar Nilsson Cancer Foundation. Lund Strategic Research Center for Stem Cell Biology and Cell Therapy is supported by a Center of Excellence grant from Swedish Foundation for Strategic Research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 121

